The understanding of atopic dermatitis has shifted beyond traditional skin barrier dysfunction to encompass a more complex immune orchestration, with basophils emerging as central conductors of the inflammatory response that affects over 230 million people worldwide. These relatively rare circulating immune cells rapidly migrate to inflamed skin sites where they become potent drivers of the type 2 immune response that characterizes eczema.
Basophils function as multifaceted inflammatory amplifiers in atopic dermatitis pathogenesis. Upon activation, they release interleukin-4 and interleukin-13, cytokines that trigger the cascade leading to epidermal thickening and dermal immune cell infiltration. Beyond these key inflammatory signals, basophils secrete histamine, leukotrienes, and interleukin-31, creating the intense itching sensation that defines the patient experience. Their IL-4 production also influences T-cell differentiation toward allergen-reactive phenotypes and promotes B-cell antibody class switching to IgE production.
This mechanistic insight carries significant clinical implications for personalized treatment approaches. The basophil activation test represents a potential breakthrough in precision medicine for atopic dermatitis, offering clinicians a blood-based tool to measure individual immune responses to specific allergens and monitor therapeutic effectiveness. Current targeted therapies including dupilumab and tralokinumab work by blocking the IL-4/IL-13 pathway that basophils help initiate, suggesting these cells may serve as biomarkers for treatment selection. The research indicates basophils contribute not only to localized skin inflammation but also to the systemic sensitization underlying atopic march—the progression from eczema to asthma and allergic rhinitis that affects many patients.